AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (1.6 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access

Susceptibility and Antimicrobial Resistance of Genital Ureaplasma Parvum

Technical Institute of Samawh, Al-Furat Al-Awsat University, Al-Samawah, Iraq
Show Author Information

Abstract

The object of this study concentrated on investigating the antimicrobial susceptibilities of Ureaplasma parvum isolates to determine the most suitable antibiotic for treating the infection. In total, 35 samples of Ureaplasma parvum isolates were included in this study. Antibiotic susceptibility was studied by broth dilution method which was for the purpose of susceptibility testing of serovar isolates of Ureaplasma parvum against eight antibiotics. The results revealed the serovar 3 isolates were fully resistant (100%) to gentamicin, azithromycin and erythromycin while susceptible at the rates of 80% to doxycycline, 60% to levofloxacin and 60% to clarithromycin. Serovar 14 isolate was revealed fully susceptible (100%) to clarithromycin, ciprofloxacin and doxycycline, while fully resistant (100%) to gentamicin and azithromycin. Serovar 1 and serovar 6 were showed to be fully resistant (100%) to azithromycin and gentamicin. Sevorar 1 was susceptible to at the rates of 70% to doxycycline, 60% to tetracycline, 90% to ciprofloxacin, 70% to levofloxacin, 70% to erythromycin and 70% to clarithromycin. Serovar 6 was susceptible at the rates of 80% to doxycycline, 100% to tetracycline, 100% to ciprofloxacin, 80% to levofloxacin, 80% to erythromycin and 80% to clarithromycin. These results evidently demonstrated that doxycycline, clarithromycin and levofloxacin should be the preferred drug when empirical treatment was required.

References

[1]

F. Santos, O. Sheehy, S. Perreault, et al., Trends in antiinfective drugs use during pregnancy. Journal of Popul Ther Clin Pharmacol, 2012, 19: 460-465.

[2]

M.J. Redelinghuys, M.M. Ehlers, A.W. Dreyer, et al., Comparison of the new Mycofast Revolution assay with a molecular assay for the detection of genital mycoplasmas from clinical specimens. South Africa Journal of BMC Infect Dis, 2013, 9: 453-455.

[3]

K.B. Waites, B. Katz, and R.L. Schelonka, Mycoplasmas and Ureaplasma as neonatal pathogens. Clin Microbiol Rev, 2005, 18: 757-789.

[4]

S. Govender, L.J. Chalkley, Tetracycline resistance genes of Ureaplasmas. South Afr. Journal of Epidemiol Infect, 2012, 27: 19-23.

[5]

B. Dhawan, N. Malhotra, V. Sreenivas, et al., Ureaplasma serovars & their antimicrobial susceptibility in patients of infertility & genital tract infections. Indian Journal of Medicine Research, 2012, 12: 991-996.

[6]

M.L. Beeton, V.J. Chalker, L.C. Jones, et al., Antibiotic resistance among clinical Ureaplasma isolates recovered from neonates in England and Wales. Antimicrob Agents Chemother, 2016, 1: 52-56.

[7]

L. Xiao, D.M. Crabb, L.B. Duffy, et al., Chromosomal mutations responsible for fluoroquinolone resistance in Ureaplasma spp. in the United States. Antimicrobial agents and chemotherapy, 2012, 56: 2780-2783.

[8]

C.T. Zhu, Z.Y. Hu, C.L. Dong, et al., Investigation of Ureaplasma urealyticum biovars and their relationship with antimicrobial resistance. Indian J Med Microbiol, 2011, 29: 288-292.

[9]

Y. Kawai, Y. Nakura, T. Wakimoto, et al., In vitro activity of five quinolones and analysis of the quinolone resistance determining region of gyrA, gyrB, parC, and parE in Ureaplasma parvum and Ureaplasma urealyticum clinical isolates from perinatal patients in Japan. Antimicrob Agents Chemother, 2015, 14: 1-12.

[10]

Y. Miura, M.S. Payne, J.A. Keelan, et al., Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection. Antimicrobial Agents and Chemotherapy, 2014, 9: 5413-5420.

[11]

Y. Kamiya, Y. Shimada, S. Ito, et al., Analysis of the quinolone-resistance determining region of the gyrA gene and the analogous region of the parC gene in Ureaplasma parvum and Ureaplasma urealyticum detected in first-void 356 urine of men with non-gonococcal urethritis. Journal of Antimicrobial Chemotherapy, 2013, 68: 480-482.

[12]

R. Krausse, S. Schubert, In vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma spp. isolated in Germany over 20 years. Clin Microbiol Infect, 2010, 16: 1649-1655.

[13]

R.M. Bayraktar, H.I. Ozerol, N. Gucluer, et al., Prevalence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum in pregnant women. Int J Infect Dis, 2010, 14: 90-95.

[14]

K.A. Stellrecht, M.A. Woron, G.N. Mishrik, et al., Comparison of multiplex PCR assay with culture for detection of genital mycoplasmas. Journal of Clin Microbiol, 2010, 42: 1528-1533.

[15]

H.P. Lin, H.X. Lu, Analysis of detection and antimicrobial resistance of pathogens in prostatic secretion from 1186 infertile men with chronic prostatitis. Journal of Zhonghua Nan Ke Xue, 2007, 13: 628-631.

[16]

D. Kilic, M.M. Basar, S. Kaygusuz, et al., Prevalence and treatment of Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma hominis in patients with non-gonococcal urethritis. Journal of Infect Dis, 2004, 57: 17-20.

[17]

M.S. Ramirez, M.E. Tolmasky, Aminoglycoside modifying enzymes. Journal of Drug resistance update, 2010, 6: 151-171.

[18]

F. Santos, O. Sheehy, S. Perreault, et al., Trends in anti-infective drugs use during pregnancy. Journal of Popul Ther Clin Pharmacol, 2012, 19: 460-465.

[19]

R. Romero, L. Yeo, J. Miranda, et al., Ablueprint for the prevention of preterm birth vaginal progesterone in women with a short cervix. Journal of Perinat Med, 2013, 1: 27-44.

[20]

B.B. Mardassi, N. Aissani, I. Moalla, et al., Evidence for the predominance of a single tet(M) gene sequence type in tetracycline-resistant Ureaplasma parvum and Mycoplasma hominis isolates from Tunisian patients. Journal of Med Microbial, 2012, 9: 1254-1261.

Nano Biomedicine and Engineering
Pages 236-241
Cite this article:
Al-khafaji GK. Susceptibility and Antimicrobial Resistance of Genital Ureaplasma Parvum. Nano Biomedicine and Engineering, 2017, 9(3): 236-241. https://doi.org/10.5101/nbe.v9i3.p236-241

424

Views

8

Downloads

1

Crossref

3

Scopus

Altmetrics

Received: 01 August 2017
Accepted: 07 September 2017
Published: 27 September 2017
© 2017 Ghofran Kadhim Al-khafaji.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Return